ArticleQuantitative imaging in medicine and surgery2026
Deep learning-based computed tomography quantification integrated with circulating tumor cells for prognostic evaluation in stage I lung adenocarcinoma.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prognosis varies among patients with early-stage lung adenocarcinoma (LUAD) even within the same clinical stage. This study aimed to evaluate the prognostic value of measurements of computed tomography (CT), circulating tumor cells (CTC), and their combinations in clinical stage I LUAD. Methods: This retrospective analysis included 183 patients at stage I peripheral LUAD who underwent preoperative thin-section chest CT and CTC detection. The maximal solid size to tumor ratio on axial image was measured by radiologists (R-MSSA%). The three-dimensional volume (3D-SV) and mass (3D-SM) of solid components were measured by deep learning, followed by calculation of the consolidation-to-tumor ratios of 3D-SV (3D-SV%) and 3D-SM (3D-SM%). The differences in recurrence rates or overall survival of CTC, CT measurements, and their combinations were compared. Multivariate Cox proportional hazards models were used to identify independent risk factors. Results: Our study results indicated that 3D-SM, 3D-SV, 3D-SM%, and CTC can stratify the recurrence risk in clinical stage I patients. For clinical stage IA patients with high values of 3D-SM, 3D-SV, R-MSSA%, or 3D-SM%, the recurrence risk showed no significant difference compared with stage IB patients. Furthermore, for stage IA patients stratified as high-risk by the integration of CTC with 3D-SM or 3D-SV, the prognosis was worse than that of stage IB patients. A model combining 3D-SM and CTC had a higher C-index [0.75; 95% confidence interval (CI): 0.70, 0.81] compared to that of 3D-SM or CTC alone. Conclusions: The integration of CTC and CT measurements can enhance the stratification ability for early-stage lung cancer patients and improve the prognosis prediction, especially for those at stage IA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.